We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Noble Life Sciences Announces Appointment of Alain Cappeluti as President
News

Noble Life Sciences Announces Appointment of Alain Cappeluti as President

Noble Life Sciences Announces Appointment of Alain Cappeluti as President
News

Noble Life Sciences Announces Appointment of Alain Cappeluti as President

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Noble Life Sciences Announces Appointment of Alain Cappeluti as President"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"I am delighted to lead Noble Life Sciences' experienced and talented team as we launch new services to expand our current offering," said Mr. Cappeluti. "A focus of our development efforts has been to establish a biomarker based platform that leverages validated cancer pathway biomarkers measured in cell lines and tumor tissues to predict and evaluate sensitivity to targeted therapeutics across cancer indications and molecular sub-types. This effort has been supported by a Translational Research Award we received in 2010 from The Department of Business and Economic Development, Maryland Biotechnology Center."

Mr. Cappeluti has more than 25 years of experience in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. Mr. Cappeluti was the second employee at HGS and was part of the team that spun out CoGenesys from HGS in 2006 until the company was sold to Teva Pharmaceuticals in 2008. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He is also a co-founder and serves on the board of OTraces, Inc., an early stage cancer diagnostics company and is on the board of and serves as a consultant to other life science companies.

Dr. Carter remarked, "I am very pleased to assume the duties of Chairman of the Board of Noble Life Sciences as I move on to a new position as President and CEO of NexImmune. Mr. Cappeluti will take the lead at Noble Life Sciences during a very exciting time as the company expands its presence in the Maryland biotechnology market."

Advertisement